Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
13 Luglio 2023 - 11:16PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
SOLICITATION/RECOMMENDATION STATEMENT
UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 3)
GreenLight
Biosciences Holdings, PBC
(Name of Subject Company)
GreenLight Biosciences Holdings, PBC
(Name of Person(s) Filing Statement)
Common Stock,
par value $0.0001 per share
(Title of Class of Securities)
39536 G105
(CUSIP Number
of Class of Securities)
Nina Thayer
General Counsel, Chief Compliance Officer & Corporate Secretary
29 Hartwell Avenue Lexington,
Massachusetts 02421 (617) 616-8188
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications
on Behalf of the Person(s) Filing Statement)
With a copy to:
Jeffrey A. Letalien R.
Kirkie Maswoswe
Goodwin
Procter LLP
The New York Times Building
620 Eighth Avenue
New
York, New York 10018
(212) 813-8800
☐ |
Check the box if the filing relates solely to preliminary communications made before the commencement of a
tender offer. |
Introduction
This Amendment No. 3 to Schedule 14D-9 (this Amendment) amends and supplements the
Solicitation/Recommendation Statement on Schedule 14D-9 (as amended from time to time, the Schedule 14D-9) originally filed by GreenLight Biosciences
Holdings, PBC, a Delaware corporation (the Company), with the Securities and Exchange Commission on June 21, 2023. The Schedule 14D-9 relates to the cash tender offer by SW MergerCo, Inc., a
Delaware corporation (Merger Sub) and a wholly-owned subsidiary of SW ParentCo, Inc., a Delaware corporation (Parent), to purchase all of the issued and outstanding Shares, other than certain excluded Shares, at an offer
price of $0.30 per Share, net to the holder of such Share, in cash, without interest and subject to any applicable withholding taxes. Parent and Merger Sub are affiliates of investment funds advised by Fall Line Capital, LLC (Fall Line).
Any capitalized term used and not otherwise defined herein shall have the meaning ascribed to such term in the Schedule 14D-9.
This Amendment is being filed to reflect certain updates as presented below.
Item 8 |
Additional Information. |
Item 8. Additional Information of the Schedule 14D-9 is hereby amended and supplemented as follows:
1. |
The paragraph under the heading Treatment of Warrants shall be deleted in its entirety and
replaced with the following paragraph: |
Pursuant to the Merger Agreement, at the Effective Time (as defined in the
Merger Agreement), each outstanding Public Warrant or Private Placement Warrant will, in accordance with its terms, automatically and without any required action on the part of the holder thereof, become a warrant exercisable for the Offer Price
that such holder would have received if such Public Warrant or Private Placement Warrant had been exercised immediately prior to the Effective Time; provided that if a holder of such Public Warrant or Private Placement Warrant properly exercises
such Public Warrant or Private Placement Warrant within thirty (30) days following the public disclosure of the consummation of the Merger, the holder of such Public Warrant or Private Placement Warrant will be entitled to receive the
Black-Scholes Warrant Value (as defined in the Warrant Agreement, dated January 13, 2021, by and between ENVI and Continental Stock Transfer & Trust Company (the Warrant Agreement)) with respect to such Public
Warrant or Private Placement Warrant, which would have been equal to approximately $0.0238 per Public Warrant as of the close of trading on May 26, 2023. In order to receive such Black-Scholes Warrant Value, the holder of a Public Warrant or
Private Placement Warrant will be required to validly exercise such Public Warrant or Private Placement Warrant and pay the exercise price thereof, which shall equal the difference of the Offer Price minus the Black-Scholes Warrant Value, within
such thirty (30) day period. The exercise price of the Public Warrants is payable only in cash. Holders of Private Placement Warrants may be exercised on a cashless basis in accordance with the terms of the Warrant Agreement.
2. |
The third bullet under the third paragraph under the heading Where You Can Find More
Information shall be deleted in its entirety and replaced with the following bullet: |
|
|
GreenLights Current Reports on Form 8-K filed on January
9, 2023, February 1, 2023, March
7, 2023, March 9, 2023, May
30, 2023 (as amended July
13, 2023) and May 31, 2023. |
SIGNATURE
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
GREENLIGHT BIOSCIENCES HOLDINGS, PBC |
|
|
By: |
|
/s/ Nina Thayer |
|
|
Name: Nina Thayer |
|
|
Title: General Counsel, Chief Compliance Officer & Corporate Secretary |
Dated: July 13, 2023
Grafico Azioni GreenLight Biosciences H... (NASDAQ:GRNA)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni GreenLight Biosciences H... (NASDAQ:GRNA)
Storico
Da Giu 2023 a Giu 2024